The Asia Pacific Atrial Fibrillation Market would witness market growth of 7.0% CAGR during the forecast period (2022-2028).
The majority of occurrences of AF are due to other medical conditions, an underlying cause may be present if there is chest discomfort or angina, hyperthyroidism (an overactive thyroid gland) symptoms including weight loss and diarrhea, or lung disease symptoms. Someone with AF may be more susceptible to problems if they have a history of heart failure, high blood pressure, rheumatic fever, diabetes, or a stroke or transient ischemic attack (TIA).
Similar to other types of fast heart rate, the presentation may be asymptomatic. Chest pain and palpitations are frequent symptoms. Rapid, uncoordinated heartbeats can limit cardiac output, or how much blood the heart pumps, which can lead to insufficient blood flow and, ultimately, insufficient oxygenation of the body's other tissues.
Breathlessness, breathlessness while lying flat, disorientation, and abrupt onset of breathlessness throughout the night are common signs of uncontrolled atrial fibrillation. Lower extremity edema, a sign of congestive heart failure, might develop as a result. People with AF may also experience lightheadedness as a result of low cardiac output.
Atrial Fibrillation can lead to respiratory discomfort because of lung congestion. The heart rate will, by definition, be higher than 100 beats per minute. Blood pressure may vary and is frequently challenging to measure since the majority of digital (oscillometric) non-invasive blood pressure monitors have issues with beat-by-beat fluctuation.
The lifestyle of the general populace in China has changed dramatically as a result of socioeconomic progress. People are exposed to cardiovascular-related risk factors more often as a result of population aging and urbanization in China, which has resulted in a rise in the incidence and prevalence of cardiovascular disease (CVD) during the previous ten years. The 2018 study on CVDs in China stated that there were around 290 million cardiovascular patients in the country, of whom 13 million had strokes and 11 million had coronary heart disease.
The China market dominated the Asia Pacific Atrial Fibrillation Market by Country in 2021; thereby, achieving a market value of $228.9 million by 2028. The Japan market is exhibiting a CAGR of 6.3% during (2022 - 2028). Additionally, The India market would experience a CAGR of 7.6% during (2022 - 2028).
Based on End User, the market is segmented into Hospitals, Specialty Clinics, and Others. Based on Type, the market is segmented into Surgical and Non-Surgical. Based on Technology, the market is segmented into Radiofrequency, Laser, Cryotherapy, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Atrial Fibrillation Market is Projected to reach USD 2.7 Billion by 2028, at a CAGR of 9.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, MicroPort Scientific Corporation, Boston Scientific Corporation, Abbott Laboratories, Medtronic PLC, BIOTRONIK SE & Co. KG, Koninklijke Philips N.V., Siemens Healthineers AG (Siemens AG) and AtriCure, Inc.
By End User
By Type
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
